D. Ercan

发表

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

P. Jänne, F. Cappuzzo, K. Okuno, 2011, Science Translational Medicine.

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

Wei Zheng, Kwok-Kin Wong, Nathanael S Gray, 2011, Cancer research.

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

Doron Lipson, Hidefumi Sasaki, Roman Yelensky, 2012, Nature Medicine.

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Levi A Garraway, Kwok-Kin Wong, Neal Rosen, 2012, Cancer discovery.

Identi fi cation of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR 2

P. Hammerman, Kwok-Kin Wong, M. Capelletti, 2015 .

Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.

P. Jänne, P. Hammerman, Kwok-Kin Wong, 2015, Cancer research.

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.

A. Redig, P. Jänne, M. Eck, 2017, Cancer research.

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

P. Jänne, N. Gray, H. Choi, 2015, Clinical Cancer Research.

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

John R. Engen, Kwok-Kin Wong, Liang Chen, 2009, Nature.

Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer

L. Garraway, P. Stephens, P. Jänne, 2013, Nature Medicine.

Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.

S. Elledge, D. Sabatini, M. Niepel, 2013, Cancer research.

Characterization of Torin 2 , an ATP-Competitive Inhibitor of mTOR , ATM , and ATR Citation

S. Elledge, D. Sabatini, M. Niepel, 2013 .

ATM , and ATR Characterization of Torin 2 , an ATP-Competitive Inhibitor of mTOR

S. Elledge, D. Sabatini, M. Niepel, 2013 .

mTOR , ATM and ATR Characterization of Torin 2 , an ATP-competitive inhibitor of

S. Elledge, D. Sabatini, M. Niepel, 2013 .

Therapeutics , Targets , and Chemical Biology Characterization of Torin 2 , an ATP-Competitive Inhibitor of mTOR , ATM , and ATR

S. Elledge, D. Sabatini, M. Niepel, 2013 .

Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors

Haikuo Zhang, Gerald Lelais, Kwok-Kin Wong, 2016 .

Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M

Aleksandra Markovets, J Carl Barrett, Geoffrey R Oxnard, 2015, Nature Medicine.

Pharmacological Targeting of the Pseudokinase Her3

P. Jänne, N. Gray, K. Westover, 2014, Nature chemical biology.

Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

Karen Cichowski, A. Letai, R. Berkowitz, 2015, Cell.

Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.

Kwok-Kin Wong, Takeshi Shimamura, P. Jänne, 2012, Cancer research.

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

P. Jänne, J. Engelman, J. Christensen, 2010, Oncogene.

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer

G. Daley, C. Paweletz, P. Jänne, 2021, Science Translational Medicine.

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.

P. Jänne, Kwok-Kin Wong, N. Gray, 2015, Cancer discovery.

Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma

P. Jänne, P. Hammerman, H. Sasaki, 2014, Clinical Cancer Research.

Discovery of selective irreversible inhibitors for EGFR-T790M.

Nathanael S Gray, P. Jänne, N. Gray, 2011, Bioorganic & medicinal chemistry letters.

Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.

P. Jänne, Kwok-Kin Wong, N. Gray, 2013, Cancer research.

Therapeutics , Targets , and Chemical Biology Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF 1 R Pathway

Kwok-Kin Wong, N. Gray, J. Christensen, 2013 .

Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF 1 R Pathway

P. Jänne, N. Gray, J. Christensen, 2012 .

Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non‐small‐cell lung cancer cell lines

P. Jänne, N. Gray, Nicholas Kwiatkowski, 2015, Molecular oncology.

Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer

Taebo Sim, Takayuki Kosaka, Nathanael S. Gray, 2016, Clinical Cancer Research.

Acquired EGFR C 797 S mediates resistance to AZD 9291 in advanced non-small cell lung cancer harboring EGFR T 790 M

Yanan, C. Paweletz, J. Barrett, 2016 .

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors

Rachel G Liao, S. Gaudet, P. Jänne, 2014, Proceedings of the National Academy of Sciences.

An Assessment of the Penile Squamous Cell Carcinoma Surfaceome for Biomarker and Therapeutic Target Discovery

S. Eschrich, S. Rogatto, J. Chahoud, 2023, Cancers.

Abstract 4832: Novel EGFR mutations that cause drug resistance to irreversible pyrimidine but not quinazoline based EGFR inhibitors

P. Jänne, N. Gray, M. Capelletti, 2012 .

Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors

P. Jänne, Jennifer L. Harris, M. Eck, 2016, Nature.

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

A. Letai, L. Garraway, P. Jänne, 2012, Cancer discovery.

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.

A. Redig, P. Jänne, M. Eck, 2017, Cancer research.

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.

P. Jänne, N. Gray, C. Pratilas, 2015, Cancer discovery.

MIT Open Access Articles Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR

M. Niepel, K. Westover, W. Hur, 2022 .